PALO ALTO, Calif.--(BUSINESS WIRE)--Theranos, Inc. today announced the appointment of Riley P. Bechtel to its Board of Directors.
Mr. Bechtel is chairman of the board and a director of Bechtel Group, Inc. Previously, he held the positions of chairman and chief executive officer from 1996-2014, president and chief executive officer from 1990-1996 and president and chief operating officer from 1989-1990. Mr. Bechtel joined the company full-time in 1981 and served in a variety of operational roles, both domestically and overseas. Prior to Bechtel, he practiced law at Thelen, Marrin, Johnson & Bridges.
Mr. Bechtel also serves as a director of Fremont Investors, Inc. and a member of Fremont Group’s Board of Advisors. He is a member of Conservation Fund's Corporate Council, Indian School of Business Governing Board, National Petroleum Council, Ocean Exploration Trust's Board of Directors, Stanford Graduate School of Business Advisory Council, and UC Davis' Board of Advisors, and was admitted to the California State Bar in November 1979.
Mr. Bechtel joins existing Theranos Board members Elizabeth Holmes, Theranos Chairman and Chief Executive Officer; Henry A. Kissinger; Richard Kovacevich; James Mattis; Samuel Nunn; William J. Perry; Gary Roughead; George P. Shultz; and Sunny Balwani, Theranos President and Chief Operating Officer.
About Theranos
Headquartered in Palo Alto, Theranos, Inc. is a consumer healthcare technology company. Theranos’ clinical laboratory offers comprehensive laboratory tests from samples as small as a few drops of blood at unprecedented low prices. Founded in 2003 by Elizabeth Holmes, Theranos’ mission is to make actionable health information accessible to people everywhere in the world at the time it matters, enabling early detection and intervention of disease, and empowering individuals with information to live the lives they want to live. www.theranos.com